These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 23243129)

  • 1. A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients.
    Neukam K; Almeida C; Caruz A; Rivero-Juárez A; Rallón NI; Di Lello FA; Herrero R; Camacho A; Benito JM; Macías J; Rivero A; Soriano V; Pineda JA
    J Antimicrob Chemother; 2013 Apr; 68(4):915-21. PubMed ID: 23243129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
    Mira JA; Valera-Bestard B; Arizcorreta-Yarza A; González-Serrano M; Torre-Cisneros J; Santos I; Vergara S; Gutiérrez-Valencia A; Girón-González JA; Macías J; López-Cortés LF; Pineda JA
    Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients.
    Guzmán-Fulgencio M; Jiménez JL; Berenguer J; Fernández-Rodríguez A; López JC; Cosín J; Miralles P; Micheloud D; Muñoz-Fernández MÁ; Resino S
    J Antimicrob Chemother; 2012 May; 67(5):1238-45. PubMed ID: 22294644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Soriano V; Núñez M; Sánchez-Conde M; Barreiro P; García-Samaniego J; Martín-Carbonero L; Romero M; González-Lahoz J
    Antivir Ther; 2005; 10(1):167-70. PubMed ID: 15751774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy.
    Pineda-Tenor D; Jiménez-Sousa MA; Rallón N; Berenguer J; Soriano V; Aldámiz-Echevarria T; García-Álvarez M; Diez C; Fernández-Rodríguez A; Benito JM; Resino S
    AIDS Res Hum Retroviruses; 2016 Mar; 32(3):226-31. PubMed ID: 26499461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients.
    De Leon LB; Tovo CV; Kliemann DA; De Mattos AA; Feltrin AA; Pacheco LS; De Almeida PR
    J Infect Dev Ctries; 2016 Aug; 10(7):762-9. PubMed ID: 27482809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients.
    Jiménez-Sousa MA; Rallón N; Berenguer J; Pineda-Tenor D; López JC; Soriano V; Guzmán-Fulgencio M; Cosín J; Retana D; García-Álvarez M; Miralles P; Benito JM; Resino S
    J Clin Virol; 2015 Apr; 65():62-7. PubMed ID: 25766991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy.
    Fernández-Rodríguez A; Berenguer J; Rallón N; Jiménez-Sousa MA; López JC; Soriano V; García-Álvarez M; Cosín J; Martínez P; Guzmán-Fulgencio M; Miralles P; Miguel Benito J; Resino S
    J Acquir Immune Defic Syndr; 2014 Oct; 67(2):113-9. PubMed ID: 25072612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
    ANRS CO13 HEPAVIH Cohort
    AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.
    Neukam K; Caruz A; Rivero-Juárez A; Barreiro P; Merino D; Real LM; Herrero R; Camacho A; Soriano V; Di Lello FA; Macías J; Rivero A; Pineda JA
    AIDS; 2013 Nov; 27(17):2715-24. PubMed ID: 23842134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV/HCV-coinfected patients.
    Pineda-Tenor D; Berenguer J; Jiménez-Sousa MA; Guzmán-Fulgencio M; Aldámiz-Echevarria T; Carrero A; García-Álvarez M; Diez C; Tejerina F; Briz V; Resino S
    J Clin Virol; 2014 Nov; 61(3):423-9. PubMed ID: 25218243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV.
    Dominguez S; Ghosn J; Cassard B; Melica G; Poizot-Martin I; Solas C; Lascaux AS; Bouvier-Alias M; Katlama C; Lévy Y; Peytavin G
    J Antimicrob Chemother; 2012 Jun; 67(6):1449-52. PubMed ID: 22396433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment for hepatitis C virus with pegylated interferon-α plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients.
    Masiá M; Robledano C; López N; Escolano C; Gutiérrez F
    J Antimicrob Chemother; 2011 Aug; 66(8):1861-8. PubMed ID: 21622971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results.
    Lacombe K; Valin N; Stitou H; Gozlan J; Thibault V; Boyd A; Poirier JM; Meynard JL; Valantin MA; Bottero J; Girard PM
    AIDS; 2013 May; 27(8):1356-9. PubMed ID: 23925383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain.
    Poveda E; Vispo E; Barreiro P; de Mendoza C; Labarga P; Fernández-Montero JV; Martin-Carbonero L; Soriano V
    Antivir Ther; 2012; 17(3):571-5. PubMed ID: 22293607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients.
    Merchante N; Rodríguez-Arrondo F; Revollo B; Merino E; Ibarra S; Galindo MJ; Montero M; García-Deltoro M; Rivero-Juárez A; Téllez F; Delgado-Fernández M; Ríos-Villegas MJ; García MA; Vera-Méndez FJ; Ojeda-Burgos G; López-Ruz MA; Metola L; Omar M; Alemán-Valls MR; Aguirrebengoa K; Portu J; Raffo M; Macías J; Pineda JA;
    AIDS; 2018 Jul; 32(11):1423-1430. PubMed ID: 29596108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.